Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
15.03. | Arctic Bioscience AS: Arctic Bioscience - Extension of share options to members of management group | 2 | Oslo Børs | ||
01.03. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Q4 2023 Operational update - Foundation for an exciting 2024 | 2 | Cision News | ||
28.02. | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Treatment start for 519 patients in the HeROPA-study | 1 | Cision News | ||
22.02. | Arctic Bioscience AS: Arctic Bioscience - Invitation to presentation of Q4 2023 operational update | 1 | Oslo Børs | ||
17.01. | Arctic Bioscience AS: Arctic Bioscience - Recruitment completed in the phase IIb HeROPA clinical trial | 2 | Oslo Børs | ||
15.12.23 | Arctic Bioscience AS: Financial calendar | 1 | Oslo Børs | ||
01.12.23 | ARCTIC BIOSCIENCE AS: Arctic Bioscience - More than 75% recruited in the phase IIb HeROPA clinical trial | 2 | Cision News | ||
02.11.23 | ARCTIC BIOSCIENCE AS: Arctic Bioscience - Q3 2023 Operational update - More than 50% recruited in the phase IIb HeROPA clinical trial | 2 | Cision News |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 39,635 | +0,75 % | QIAGEN N.V.: Bessere Zusammenarbeit im Gesundheitswesen: QIAGEN stellt QIAstat-Dx Analyzer 2.0 mit Fernzugriff auf Testergebnisse vor | QIAstat-Dx Analyzer 2.0 mit Software-Version 1.6 ermöglicht mobilen Zugriff auf Testergebnisse, optimiert diagnostische Prozesse und verbessert die Patientenversorgung // QIAstat-Dx Analyzer 2.0 bietet... ► Artikel lesen | |
EVOTEC | 14,470 | +0,66 % | Übernahmen im BioTech-Sektor! Nach MorphoSys könnten Evotec, Medigene oder sogar Bayer folgen! | Im Jahr 2022 erhielten insgesamt 18,5 Mio. Menschen die schockierende Diagnose "Krebs". Aktuelle Trends sprechen leider dafür, dass diese Zahl in den nächsten Jahren nicht kleiner wird. Dank wachsender... ► Artikel lesen | |
MORPHOSYS | 67,20 | 0,00 % | Morphosys mit EILMELDUNG: Experte setzt SCHOCKIERENDES Kursziel - Sofortiges HANDELN erforderlich! | ||
PRAXIS PRECISION MEDICINES | 57,69 | -2,53 % | Praxis Precision Medicines, Inc.: Praxis Precision Medicines Reports Positive Results of PRAX-628 Study Evaluating Photo Paroxysmal Response (PPR) Achieving 100% Response in Treated Patients | In the 45 mg cohort, 100% of patients achieved a complete response In the 15 mg cohort, 80% of patients achieved a complete response and 20% achieved a partial response Safety was consistent with... ► Artikel lesen | |
VIKING THERAPEUTICS | 75,40 | -2,15 % | Zweite Chance: Nach Gewinnmitnahmen bietet diese Aktie eine neue Gewinnchance | ||
BIONTECH | 86,10 | +0,19 % | BioNTech-Aktie: Was für ein Ding! | Bernd Wünsche (Gurupress.de) - BioNTech wandert weiter die Kursleiter hinunter. Die Mainzer verloren am Mittwoch gut -4 %. Das ist allerdings auch ein Ausfluss der Zahlen, die das Unternehmen nun präsentiert... ► Artikel lesen | |
RECURSION PHARMACEUTICALS | 10,055 | -1,81 % | Recursion Pharmaceuticals: Recursion Publishes Annual Environmental, Social and Governance Report | ||
SUMMIT THERAPEUTICS | 4,125 | +10,59 % | Analysts Eye Summit Therapeutics' Ivonescimab As Potential Challenger To Merck's Keytruda in Lung Cancer Treatment | ||
4D MOLECULAR THERAPEUTICS | 31,470 | -11,87 % | 4D Molecular Therapeutics, Inc.: 4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis | Conducted initial pivotal study interactions with the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA); Company has clear registration path for 4D-710 for treatment of cystic... ► Artikel lesen | |
ANNEXON | 7,300 | -8,52 % | Annexon Biosciences: Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones | Pivotal Phase 3 Data for ANX005 in Guillain-Barré Syndrome (GBS) Expected in Second Quarter 2024 Initiation of Pivotal Phase 3 ANX007 ARCHER II Trial in Geographic Atrophy (GA) Expected in mid-2024... ► Artikel lesen | |
NUVALENT | 74,78 | -3,26 % | Nuvalent, Inc.: Nuvalent Receives U.S. FDA Breakthrough Therapy Designation for NVL-520 | CAMBRIDGE, Mass., Feb. 27, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven... ► Artikel lesen | |
MOONLAKE IMMUNOTHERAPEUTICS | 50,19 | +1,03 % | Ascendis Pharma and MoonLake Immunotherapeutics dropped from Wedbush list | ||
IMMUNOVANT | 32,020 | -0,90 % | Pre-market Movers: Kaival Brands, Lufax Holding, Tourmaline Bio, Laser Photonics Corporation, Immunovant | BRUSSELS/FRANKFURT/PARIS (dpa-AFX) - The following are some of the stocks making big moves in Thursday's pre-market trading (as of 08.00 A.M. ET).In the Green Kaival Brands Innovations Group... ► Artikel lesen | |
SPRINGWORKS THERAPEUTICS | 49,890 | +0,65 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Initiates Rolling Submission of New Drug Application to the FDA for Mirdametinib for the Treatment of Children and Adults with NF1-PN | STAMFORD, Conn., March 04, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, announced... ► Artikel lesen | |
BEAM THERAPEUTICS | 33,350 | -1,68 % | Beam Therapeutics To Start Clinical Study Of BEAM-302 In Alpha-1 Antitrypsin Deficiency In UK | WASHINGTON (dpa-AFX) - Beam Therapeutics Inc. (BEAM) Tuesday said the UK's Medicines and Healthcare Products Regulatory Agency gave clearance to the company's clinical trial authorization (CTA)... ► Artikel lesen |